Analgesics in Australia

Abstract
Value sales of analgesics continue to rise in Australia in 2022 following a particularly strong performance the previous year when demand was partly driven by the ongoing effects of the pandemic and stockpiling tendencies. Whilst habit persistence is maintaining overall demand for popular analgesics such as acetaminophen and ibuprofen, the easing of restrictions in Australia, in line with the country’s rollout of its vaccination campaign and a fall in COVID-19 cases, has led to greater mobility...

Euromonitor International's Analgesics in Australia report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales data 2017-2021, allowing you to identify the sectors driving growth. Forecasts to 2026 illustrate how the market is set to change.

Product coverage: Systemic Analgesics, Topical Analgesics/Anaesthetic.

Data coverage: market sizes (historic and forecasts), company shares, brand shares and distribution data.

Why buy this report?
* Get a detailed picture of the Analgesics market;
* Pinpoint growth sectors and identify factors driving change;
* Understand the competitive environment, the market’s major players and leading brands;
* Use five-year forecasts to assess how the market is predicted to develop.

Content
Analgesics in Australia
January 2023

List Of Contents And Tables

ANALGESICS IN AUSTRALIA
KEY DATA FINDINGS
2022 DEVELOPMENTS
Rise in common colds and illnesses post-pandemic leads to further demand for analgesics in Australia
Panic buying continues to place pressure on supply chain of analgesics
Reckitt Benckiser (Australia) Pty Ltd launches next generation of Nurofen with Nurofen Meltlets
PROSPECTS AND OPPORTUNITIES
Growth rates to gradually normalise over forecast period but demand will remain high despite rising unit prices
Associated harmful side effects could trigger more conservative use of analgesics
Chronic pain expected to rise over the forecast period contributing to sales of analgesics
CATEGORY DATA
Table 1 Sales of Analgesics by Category: Value 2017-2022
Table 2 Sales of Analgesics by Category: % Value Growth 2017-2022
Table 3 NBO Company Shares of Analgesics: % Value 2018-2022
Table 4 LBN Brand Shares of Analgesics: % Value 2019-2022
Table 5 Forecast Sales of Analgesics by Category: Value 2022-2027
Table 6 Forecast Sales of Analgesics by Category: % Value Growth 2022-2027
CONSUMER HEALTH IN AUSTRALIA
EXECUTIVE SUMMARY
Consumer health in 2022: The big picture
2022 key trends
Competitive landscape
Retailing developments
What next for consumer health?
MARKET INDICATORS
Table 7 Consumer Expenditure on Health Goods and Medical Services: Value 2017-2022
Table 8 Life Expectancy at Birth 2017-2022
MARKET DATA
Table 9 Sales of Consumer Health by Category: Value 2017-2022
Table 10 Sales of Consumer Health by Category: % Value Growth 2017-2022
Table 11 NBO Company Shares of Consumer Health: % Value 2018-2022
Table 12 LBN Brand Shares of Consumer Health: % Value 2019-2022
Table 13 Penetration of Private Label in Consumer Health by Category: % Value 2017-2022
Table 14 Distribution of Consumer Health by Format: % Value 2017-2022
Table 15 Distribution of Consumer Health by Format and Category: % Value 2022
Table 16 Forecast Sales of Consumer Health by Category: Value 2022-2027
Table 17 Forecast Sales of Consumer Health by Category: % Value Growth 2022-2027
APPENDIX
OTC registration and classification
Vitamins and dietary supplements registration and classification
Self-medication/self-care and preventive medicine
Switches
Summary 1 OTC: Switches 2021-2022
DISCLAIMER
DEFINITIONS
SOURCES
Summary 2 Research Sources